Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BinD19 in R/R B-cell ALL and Lymphoma
NCT03156101Phase 2Unknown
- Sponsor
- BinDeBio
- Start
- Mar 2017
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of bind-19 in B cell acute lymphoblastic leukemia (B-ALL), B cell lymphoma, sponsored by BinDeBio. Status: unknown.
02
Drugs
bind-19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT03156101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156101.